• Search
  • Contact Us
  • Blogs
  • Healthcare Professionals
    • Blogs
      • Expand OAB Care
      • Sterile Endoscopy
    • Specialties
      • Urology
      • Endourology
      • Gynecology
      • Bariatric Medicine
      • Critical Care
      • Gastroenterology
      • Infection Prevention
      • Otolaryngology
      • Pulmonology
      • Senior Living
    • Products
      • PrimeSight
        • Clinical Data
        • Flexible Endoscopes
        • Rigid Endoscopes
        • Video System
        • Light Sources
        • Accessories
      • EndoSheath
        • Clinical Data
      • Urgent PC
        • Clinical Data
      • Macroplastique
        • Clinical Data
    • Reimbursement
      • Urgent PC
        • Coverage Finder
        • Prior Auth
        • Appeals
      • Macroplastique
        • Prior Auth
        • Appeals
      • Endoscopy
    • Upcoming Meetings
    • Resource Center
  • Patients
    • Find a Provider
    • Conditions
      • Overactive Bladder
      • Stress Urinary Incontinence
    • Endoscope Safety
    • Products
      • PrimeSight
      • Macroplastique
        • Stories
      • Urgent PC
        • Stories
    • Resource Center
    • MyPTNS
  • Customer Care
    • Product Ordering
      • Ordering Questions
      • New Account Form
      • Service Plans
      • Terms and Conditions
    • Repair and Support
      • Technical Support Questions
      • Returns and Feedback
        • Incident Report
      • Product Instructions
    • Contact Customer Care
  • About Us
    • Locations
    • History
    • Affiliations
    • Careers
      • Available Positions
Cogentix Medical
Menu

Prospective study of polydimethylsiloxane vs dextranomer/hyaluronic acid injection for treatment of vesicoureteral reflux.

Moore, K, Bolduc, S. (2014). J Urol, 192(6), 1794-800.

Purpose: Endoscopic injection of a bulking agent is becoming a first-line treatment for low grade vesicoureteral reflux. We prospectively compared the efficacy of 2 such products commercially available in Canada.

Materials and Methods: A total of 275 patients with documented grade I to V vesicoureteral reflux were prospectively enrolled in a comparative study between April 2005 and February 2011 to be randomly treated endoscopically with either polydimethylsiloxane (Macroplastique®) or dextranomer/hyaluronic acid copolymer (Deflux®). Of the ureters 202 were treated with polydimethylsiloxane and 197 with dextranomer/hyaluronic acid copolymer. Patients were followed with voiding cystourethrography at 3 months and renal ultrasonography at 3 months and at 1 year. Median followup was 4.3 years. The primary outcome was surgical success (resolution vs nonresolution), and secondary outcomes included occurrence of adverse events.

Results: Vesicoureteral reflux was fully corrected in 182 of 202 ureters (90%) treated with polydimethylsiloxane, compared to 159 of 197 (81%) treated with dextranomer/hyaluronic acid copolymer (p <0.05). Obstruction was found in 5 ureters. Univariate and multivariate analyses did not allow identification of any characteristics that could explain the significant difference in the success rates except for the type of product used.

Conclusions: We present the largest known prospective evaluation comparing 2 bulking agents for the treatment of vesicoureteral reflux. Endoscopic injection of polydimethylsiloxane resulted in a better success rate than dextranomer/hyaluronic acid copolymer. The rate of resolution obtained with the latter is lower than those previously published due to the inclusion of high grade reflux.

Source: Pub Med 24928269

  • Twitter
  • Facebook
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Center
© 2019 Cogentix Medical. Some Cogentix Medical products may not be available in certain regions.

What can we help you with?

  • Find A Provider
  • Customer Care
  • Expert Information